arsenic low-dose / Phebra, University of Wollongong - LARVOL DELTA

Phebra and University of Wollongong’s promising drug development for leukemias and pancreatic cancer (Phebra Press Release) - "Australian pharmaceutical company Phebra and the University of Wollongong (UOW) have announced a new six-year collaboration. Agreement to continue promising research and development (R&D) and trials of patented and targeted arsenic compounds for the treatment of acute myeloid leukemias and pancreatic cancer...The new molecule uses a targeting system to deliver very low amounts of the active ingredient arsenic to specific cancers so that we can reduce the off target side effects and expand the therapeutic potential to difficult to treat cancers. The drug has shown positive outcomes in acute myeloid leukemia (AML) and pancreatic cell lines."

Licensing / partnership • Preclinical • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Leukemia • Oncology • Pancreatic Cancer • Solid Tumor